Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

Sponsor
Philipps University Marburg
Study ID
NCT04359290
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib administration — DRUG
    Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.

Study Details

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.

Key Dates

Start date
Jul 1, 2020
Status verified
Nov 2020
Primary completion
Dec 31, 2020
Completion
Jul 30, 2021

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib treatment
    Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days

Primary Outcome Measure

Overall survival [ Time Frame: 28 days after registration into trial ]

Related Studies